ChemoCentryx (CCXI) and Argos Therapeutics (ARGS) Critical Review

ChemoCentryx (NASDAQ: CCXI) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Volatility & Risk

ChemoCentryx has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Earnings & Valuation

This table compares ChemoCentryx and Argos Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx $11.94 million 33.33 -$39.96 million ($0.60) -13.60
Argos Therapeutics $950,000.00 12.03 -$53.02 million ($1.26) -0.10

ChemoCentryx has higher revenue and earnings than Argos Therapeutics. ChemoCentryx is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for ChemoCentryx and Argos Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 1 0 2.50
Argos Therapeutics 0 3 0 0 2.00

Argos Therapeutics has a consensus price target of $1.20, indicating a potential upside of 823.08%. Given Argos Therapeutics’ higher possible upside, analysts plainly believe Argos Therapeutics is more favorable than ChemoCentryx.


This table compares ChemoCentryx and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A -67.57% -20.43%
Argos Therapeutics -13,750.64% N/A -120.95%

Institutional & Insider Ownership

48.9% of ChemoCentryx shares are owned by institutional investors. Comparatively, 18.4% of Argos Therapeutics shares are owned by institutional investors. 26.2% of ChemoCentryx shares are owned by insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


ChemoCentryx beats Argos Therapeutics on 10 of the 14 factors compared between the two stocks.

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

About Argos Therapeutics

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply